18 terminated. 18 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Terminated 18 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Influenza, Human: new trials by email Literature Review of Influenza, Human trials Research Report on Influenza, Human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection SNG001, Placebo - Viral Pneumonia | Phase 2 | Terminated | Synairgen Research Ltd. | 11 | 2025-09-02 | 2026-09-14 |
| CX-4945 in Viral Community Acquired Pneumonia CX-4945 (SARS-CoV-2 domain), Placebo (SARS-CoV-2 domain), CX-4945 (Influenza virus domain) - Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia | Phase 2 | Terminated | Senhwa Biosciences, Inc. | 45 | 2024-03-20 | 2026-01-08 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo - Influenza A | Phase 2 | Terminated | Vir Biotechnology, Inc. | 2977 | 2022-10-30 | 2024-09-19 |
| Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza Baloxavir Marboxil, Placebo, Oseltamivir - Influenza | Phase 2 / Phase 3 | Terminated | Weill Medical College of Cornell University | 2 | 2022-04-22 | 2025-02-26 |
| Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. Nivolumab, Ipilimumab, Influenza vaccine - Pancreatic Cancer | Phase 2 | Terminated | Herlev Hospital | 19 | 2021-11-05 | 2024-05-28 |
| Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults MVA-NP+M1, Saline - Influenza | Phase 2 | Terminated | Barinthus Biotherapeutics | 2364 | 2019-03-18 | 2021-04-26 |
| Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo - Influenza, Human | Phase 2 | Terminated | Novavax | 1375 | 2018-09-24 | 2022-11-04 |
| Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection. Oseltamivir, Diltiazem, Placebos - Flu | Phase 2 | Terminated | University Hospital, Lille | 85 | 2017-12-23 | 2023-02-06 |
| Improved Novel VaccIne CombinaTion InflUenza Study Seasonal influenza vaccine, MVA-NP+M1, Sodium chloride - Influenza | Phase 2 | Terminated | Barinthus Biotherapeutics | 862 | 2017-10-13 | 2018-11-23 |
| Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo - Virus Diseases | Phase 2 | Terminated | GlaxoSmithKline | 10 | 2017-01-19 | 2020-11-30 |
| Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) Lenalidomide, Influenza Vaccine, Pneumovax Vaccine - Hematologic Disorder | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2014-11-24 | 2018-09-20 |
| Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza 20 mg laninamivir octanoate, Placebo, 40 mg laninamivir octanoate - Influenza | Phase 1 / Phase 2 | Terminated | Biota Scientific Management Pty Ltd | 15 | 2013-11-01 | 2025-01-13 |
| Vitamin D Supplementation and the Immune Response Vitamin D (drug) - D Vitamin Deficiency Patients | Phase 2 | Terminated | University Hospital, Clermont-Ferrand | 37 | 2013-06-01 | 2026-08-06 |
| Safety Study of FluMist With and Without Ampligen Poly I:Poly C12U 50 ug, Poly I:Poly C12U 200 ug, Poly I:Poly C12U 500 ug - Influenza, Human | Phase 1 / Phase 2 | Terminated | AIM ImmunoTech Inc. | 55 | 2012-04-01 | 2018-07-26 |
| Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children GSK Bio's influenza vaccine GSK2584786A, different formulations, GSK Bio's influenza vaccine GSK2321138A, Fluarix™ - Influenza, Influenza Vaccines | Phase 2 | Terminated | GlaxoSmithKline | 4 | 2010-09-30 | 2020-10-30 |
| Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza Nitazoxanide, Placebo - Influenza | Phase 2 | Terminated | Romark Laboratories L.C. | 79 | 2010-01-01 | 2018-04-05 |
| Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine, Infanrix™-IPV/Hib, Prevenar - Influenza | Phase 2 | Terminated | GlaxoSmithKline | 8 | 2009-11-17 | 2019-02-15 |
| Development of Immune Globulin Treatment for Avian Flu H5N1 vaccine, Apheresis - Infectious Diseases, Influenza | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 126 | 2006-08-01 | 2018-07-31 |
Adenoviridae Infections (1) · Agammaglobulinemia (1) · COVID-19 (1) · Communicable Diseases (1) · Community-Acquired Pneumonia (1) · Coronavirus Infections (1) · Hematologic Diseases (1) · Influenza in Birds (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Pancreatic Neoplasms (1) · Paramyxoviridae Infections (1) · Pneumonia, Viral (1) · Virus Diseases (1)
Infections (18) · Orthomyxoviridae Infections (18) · RNA Virus Infections (18) · Respiratory Tract Diseases (18) · Respiratory Tract Infections (18) · Virus Diseases (17) · Coronaviridae Infections (2) · Disease Attributes (2) · Lung Diseases (2) · Neoplasms (2) · Nidovirales Infections (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Pneumonia (2) · Animal Diseases (1)
Influenza Vaccines (4) · Oseltamivir (3) · Sodium Chloride (2) · Blood Component Removal (1) · CS 8958 (1) · Diltiazem (1) · FluMist (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Ipilimumab (1) · Lactose (1) · Lenalidomide (1) · Nivolumab (1) · Pharmaceutical Preparations (1) · SARS-CoV-2 inactivated vaccines (1) · Sugars (1)
GlaxoSmithKline (3) · Barinthus Biotherapeutics (2) · AIM ImmunoTech Inc. (1) · Biota Scientific Management Pty Ltd (1) · Herlev Hospital (1) · M.D. Anderson Cancer Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novavax (1) · Romark Laboratories L.C. (1) · Senhwa Biosciences, Inc. (1) · Synairgen Research Ltd. (1) · University Hospital, Clermont-Ferrand (1) · University Hospital, Lille (1) · Vir Biotechnology, Inc. (1) · Weill Medical College of Cornell University (1)
United States (10) · France (2) · United Kingdom (2) · Australia (1) · Denmark (1) · Norway (1) · Romania (1) · Russia (1) · Spain (1) · Sweden (1) · Taiwan (1)
Alessandra Ferrajoli, MD,BS (1) · Christopher Butler (1) · David R Strayer, MD (1) · H. Clifford Lane, M.D. (1) · Inna M Chen (1) · James Vandeleur, MD (1) · Jason Huang, M.D. (1) · Jolanta Airey, Dr (1) · Julien Poissy, MD, PhD (1) · Mirella Salvatore, MD (1)
PMID 19569973, PMID 21386997, PMID 25128802, PMID 30800121, PMID 32089822, PMID 33146720, PMID 35305317, PMID 39036981, PMID 42836590
2016 (2)